---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-039948"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:40:07.698924+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO

## Summary
- Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.
- Upfront payment $100M plus $75M escrowed milestone; up to $323M dev/reg milestones, $1.488B sales milestones, and low single to low double-digit tiered royalties.
- Jason O'Byrne appointed EVP and CFO effective Oct 2, 2024; base salary $530K, target bonus 45%, sign-on $450K, equity awards of 150K options and 75K RSUs.
- Clinical assets: SAR446309 (HER2) in Phase 1, SAR446329 (PSMA) in Phase 1, SAR446368 (EGFR) IND active, Phase 1 start expected Q1 2025.

## SEC filing metadata
- accession: 0001628280-24-039948
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828024039948/0001628280-24-039948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828024039948/vir-20240906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-039948
- JSON: https://secwatch.observer/filing/0001628280-24-039948.json
- Plain text: https://secwatch.observer/filing/0001628280-24-039948.txt

## Source-grounded claims
- claim_id: 5824479bda
  claim: Jason O'Byrne was appointed as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..
  evidence_excerpt: the Company announced that Jason O’Byrne, MBA, has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 2, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828024039948/0001628280-24-039948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.